Subsequent Events	12 Months Ended
Dec. 31, 2011
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	(15) SUBSEQUENT EVENTS On March 9, 2012, ZND entered into an asset purchase agreement with NeuroDyne Medical Corp (“NeuroDyne”) to acquire substantially all of NeuroDyne’s assets for the sum of $300,000 payable at closing ($145,000 in cash and 266,478 shares of restricted common stock valued at $175,000), and an additional $100,000 in cash payable sixty days from the close date (the “Transaction”). The Transaction simultaneously closed. The Transaction also provides for additional contingent consideration, based on a percentage of net revenue generated by NeuroDyne products over the next seven years. The acquisition is to be accounted for under the acquisition method of accounting. Due to the timing of the transaction, the Company has not yet developed a preliminary purchase price allocation for the Transaction. NeuroDyne, located in Cambridge, Massachusetts, is an 18 year old manufacturer of advanced medical devices for non-invasive measurement of sEMG and autonomic nervous systems. The devices are used for evaluation and treatment of neurological and neuromuscular disorders as well as education and research. NeuroDyne’s products include medical instruments, sensors, disposable electrodes and software that offer sEMG, EKG, EEG, respiration, skin temp, EDR, EDL, peripheral blood flow, IBI, heart rate, and heart rate variability. The products are sold world wide and are used by healthcare providers, educators and researchers.

Subsequent Events

12 Months Ended

Dec. 31, 2011

(15) SUBSEQUENT EVENTS

On March 9, 2012, ZND entered into an asset purchase agreement with NeuroDyne Medical Corp (“NeuroDyne”) to acquire substantially all of NeuroDyne’s assets for the sum of $300,000 payable at closing ($145,000 in cash and 266,478 shares of restricted common stock valued at $175,000), and an additional $100,000 in cash payable sixty days from the close date (the “Transaction”). The Transaction simultaneously closed. The Transaction also provides for additional contingent consideration, based on a percentage of net revenue generated by NeuroDyne products over the next seven years. The acquisition is to be accounted for under the acquisition method of accounting. Due to the timing of the transaction, the Company has not yet developed a preliminary purchase price allocation for the Transaction. NeuroDyne, located in Cambridge, Massachusetts, is an 18 year old manufacturer of advanced medical devices for non-invasive measurement of sEMG and autonomic nervous systems. The devices are used for evaluation and treatment of neurological and neuromuscular disorders as well as education and research. NeuroDyne’s products include medical instruments, sensors, disposable electrodes and software that offer sEMG, EKG, EEG, respiration, skin temp, EDR, EDL, peripheral blood flow, IBI, heart rate, and heart rate variability. The products are sold world wide and are used by healthcare providers, educators and researchers.